Transdiscal Administration Of Specific Inhibitors Of Pro-Inflammatory Cytokines
The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.
1 - 20 . (canceled)
21 . A method of treating degenerative disc disease in an intervertebral disc having a nucleus pulposus, comprising, administering autologous, uncultured stem cells into a degenerated intervertebral disc.
22 . The method of claim 21 , wherein the stem cells are concentrated prior to being administered into the intervertebral disc.
23 . The method of claim 22 , wherein the stem cells are concentrated using centrifugation.
24 . The method of claim 22 , wherein the stem cells are concentrated using filtration.
25 . The method of claim 21 , wherein the stem cells are administered to the disc using a carrier.
26 . The method of claim 21 , wherein the stem cells are derived from bone marrow aspirate.
27 . The method of claim 21 , wherein there is an additional step of administering a therapeutic agent into the intervertebral disc.
28 . The method of claim 27 , wherein the therapeutic agent is selected from the group consisting of growth factors, differentiation factors, and nutritional supplements.
29 . The method of claim 28 , wherein the therapeutic agent is a growth factor.
30 . The method of claim 27 wherein the therapeutic agent and the stem cells are administered into the intervertebral disc with saline.
31 . The method of claim 21 , wherein the stem cells are derived from adipose tissue.
32 . The method of claim 27 , wherein the step of administering the therapeutic agent occurs simultaneously with the step of administering the stem cells to the disc.
33 . The method of claim 27 , wherein the step of administering the therapeutic agent occurs prior to the step of administering the stem cells to the disc.
34 . The method of claim 27 , wherein the step of administering the therapeutic agent occurs after the step of administering the stem cells to the disc.
35 . The method of claim 21 , wherein the stem cells are administered into the disc with an anticoagulant.
36 . The method of claim 21 , wherein the stem cells are administered into the disc with a nutritional supplement.
37 . The method of claim 21 , wherein the stem cells are administered into the disc with autologous platelet concentrate.
38 . The method of claim 21 , wherein the stem cells are administered into the nucleus pulposus.
39 . The method of claim 21 , wherein the stem cells are administered into the annulus fibrosus.
40 . The method of claim 21 , wherein a portion of the nucleus pulposus is removed prior to administering the stem cells into the intervertebral disc.
41 . The method of claim 21 , wherein the administering of the stem cells is accomplished through a needle.
42 . The method of claim 41 , wherein the needle has a maximum gauge of 24 gauge.
43 . A method of treating degenerative disc disease in an intervertebral disc having a nucleus pulposus, comprising, administering into the nucleus pulposus of the degenerated intervertebral disc a composition comprising:
i) mesenchymal progenitor cells from autologous bone marrow;
ii) demineralized bone matrix; and
iii) hyaluronic acid.
44 . A method of treating degenerative disc disease in an intervertebral disc having a nucleus pulposus, comprising:
a) contacting a substrate comprising demineralized bone matrix and hyaluronic acid with autologous bone marrow to produce a composition; and
b) administering the composition into the nucleus pulposus of the degenerated intervertebral disc.